| Oct 29 |
89bio: Surviving A Competitive Space - For Now
|
| Oct 18 |
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
|
| Oct 17 |
State Street Corp's Strategic Acquisition in 89bio Inc
|
| Oct 15 |
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
|
| Sep 30 |
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
|
| Sep 16 |
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
|
| Aug 29 |
89bio to Participate in Upcoming Investor Conferences
|
| Aug 7 |
89bio: Bullish In Light Of Further MOA Being Established By Peer
|
| Aug 7 |
89bio names Francis Sarena as COO
|
| Aug 7 |
89bio Appoints Francis Sarena as Chief Operating Officer
|
